Orencia-Kasuistik

Psenak, O; Orencia – Patientenfälle aus dem Alltag; 26.02.2015; Salzburg. 2015.

Interessante Präsentationen am europäischen Krebskongress: Neue Daten beim Mammakarzinom

Gampenrieder, SP; Spectrum Onkologie. 2015. 05: 34-36.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger, U; Trneny, M; Melzer, H; Praxmarer, M; Nawarawong, W; Ben Yehuda, D; Goldstein, D; Mihaljevic, B; Ilhan, O; Ballova, V; Hedenus, M; Hsiao, LT; Au, WY; Burgstaller, S; Weidinger, G; Keil, F; Dittrich, C; Skrabs, C; Klingler, A; Chott, A; Fridrik, MA; Greil, R; Haematologica. 2015; 100(7):955-963

Response to comment by P. Vassilakopoulos and colleagues.

Jaeger, U; Praxmarer, M; Greil, R; Haematologica. 2015; 100(11):e482

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer, F; Melchardt, T; Tränkenschuh, W; Neureiter, D; Moser, G; Magnes, T; Weiss, L; Schlattau, A; Hufnagl, C; Ricken, G; Höftberger, R; Greil, R; Egle, A; BMC Cancer. 2015; 15:996

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Gisslinger, H; Zagrijtschuk, O; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Them, NC; Kadlecova, P; Klade, C; Greil, R; Blood. 2015; 126(15):1762-1769

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.

Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A; J Natl Compr Canc Netw. 2015; 13(12):1501-1508

Cytomegalovirus reactivation and its clinical impact in patients with solid tumors.

Schlick, K; Grundbichler, M; Auberger, J; Kern, JM; Hell, M; Hohla, F; Hopfinger, G; Greil, R; Infect Agent Cancer. 2015; 10:45

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.

Melchardt, T; Hufnagl, C; Magnes, T; Weiss, L; Hutarew, G; Neureiter, D; Schlattau, A; Moser, G; Gaggl, A; Tränkenschuh, W; Greil, R; Egle, A; BMC Cancer. 2015; 15:725

CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.

Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Kruschinski, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN; Oncotarget. 2015; 6(14):12048-12060